For content to make a real impact, it can no longer just be better—it has to be exponentially better. Search results are saturated, readers are increasingly skeptical, and Google is heavily ...

What Happened? Shares of biotech company 10x Genomics (NASDAQ:TXG) jumped 10.5% in the morning session after the company reported better-than-expected fourth-quarter results, highlighted by a smaller ...

10x Genomics' share price is down nearly 15% today and >70% year-to-date. The company offers innovative products for biological analysis but faces heavy losses and declining revenues of key products.

10x Genomics is bolstering its commitment to scaling single cell experiments through the acquisition of Scale Biosciences. 10x has agreed to pay $30 million in cash and stock upfront, plus an ...

Laboratories looking to expand into or improve upon their single cell capabilities have some new products to consider from the two leading public companies in the space. 10x Genomics has launched two ...

Biotech company 10x Genomics (NASDAQ:TXG) reported in Q4 CY2025, but sales were flat year on year at $166 million. The ...

10x Genomics (TXG) came out with quarterly earnings of $0.28 per share, beating the Zacks Consensus Estimate of a loss of $0.35 per share. This compares to a loss of $0.32 per share a year ago. These ...